Deal To Fight Zika Virus Boosts NIH, CDC Efforts, But Offers No FDA Review Dollars
This article was originally published in The Gray Sheet
A $1.1bn agreement between the House and Senate to fund the emergency Zika virus response gives millions of dollars to the Centers for Disease Control and Prevention, NIH, and HHS's biodefense unit, but leaves FDA with no extra funds to support reviews of Zika products. The deal would take dollars from Ebola funding and HHS Affordable Care Act efforts as an offset, and is opposed by the president, who says he will veto it.
You may also be interested in...
When Congress returns to work after the summer recess, the House and Senate medical innovation packages may gain momentum as legislators seek a “feather in the cap” for reelection campaigns, and House Energy and Commerce Committee Chair Fred Upton and Vice President Joe Biden look to cement legacies, say legislative analysts. Also, a Zika virus funding rider is expected be attached to a continuing resolution.
The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.